IL17A and metabolic dysfunction-associated steatohepatitis: Multiple studies have demonstrated that blocking IL-17A or its receptor IL-17RA results in reduced hepatic steatosis, inflammation, and fibrosis, highlighting its significance in the pathogenesis of NASH (51, 54, 60).